Peptides for use in the treatment of alzheimer's disease
OwnerNathaniel Gavin Nicolas Miltoninventor
Life of this patent
Estimating the term…
Abstract
Anti-sense peptides that correspond to Amyloid-β protein residues 1-43 are identified, and are used to identify protein binding sites on enzymes that interact with Amyloid-β. The anti-sense peptides can be used as, or to identify, therapeutic agents that prevent Amyloid-β cytotoxicity, and may be useful in the treatment of Alzheimer's disease. The anti-sense peptides show sequence similarity to the protein kinase cdc2, and it has now been found that the cytotoxic form of Aβ is phosphorylated.
Claims40
A peptide comprising the anti-sense sequence of Aβ 1-43 (SEQ ID NO. 2), or a fragment thereof capable of binding to the Aβ protein within the Aβ 1-43 region, or a homologue of the peptide or the fragment having the same hydropathic profile or at least 60% sequence identity.
A peptide according to any preceding claim, comprising any of the sequences identified herein as SEQ ID NOS. 2, 6, 7, 8, 9 or 10 or a fragment thereof capable of binding to the Aβ protein within the Aβ1-43 region.
A peptide according to any preceding claim, having a therapeutic or diagnostic agent bound thereto.
A peptide according to any preceding claim for use in therapy.
A phosphorylated Aβ protein, or a fragment thereof, for use in therapy.
An antibody raised against a peptide comprising any of the sequences defined herein as SEQ ID NOS. 13 to 21.
An antibody raised against a peptide comprising any of the sequences defined herein as SEQ ID NOS. 13 to 16.
Use of a peptide comprising the amino acid sequence Aβ 1-43, or a fragment thereof capable of binding to cyclin-dependent kinase, in the manufacture of a medicament for therapy of a condition mediated by phosphorylation of Aβ.
Use of a protein kinase inhibitor in the manufacture of a medicament for the treatment of Alzheimer's disease.
A method for determining whether a patient is at risk from Alzheimer's disease, comprising analysing a sample from the patient that contains Aβ to determine whether Aβ is phosphorylated, where the detection of phosphorylation indicates a risk of Alzheimer's disease.
An assay for the identification of an agent that inhibits the interaction of Aβ protein with other proteins, comprising contacting Aβ protein or a fragment thereof, with a target agent and a peptide that binds to Aβ (or the fragment), and determining whether the agent inhibits the peptide from binding to Aβ, compared to a control assay carried out in the absence of the peptide.
A vaccine composition, comprising a phosphorylated Aβ protein, or a fragment thereof, and a pharmaceutically acceptable diluent or adjuvant.
A vaccine composition, comprising a peptide comprising any of the sequences defined herein as SEQ ID NO. 13 to SEQ ID NO. 17.
A compound that blocks the activity of phosphorylated Aβ protein.
Dependencies are inferred from the claim text.